The FDA has recommended but has not made it a requirement for indoor tanning bed operators to limit teens to three or fewer tanning bed sessions in the first week. Researchers from San Diego State University and colleagues have indicated that only about 11% indoor tanning bed operators did so, and 71% of tanning bed operators said they would allow a teen to tan seven days a week.

Solta Medical Inc has received approval from the FDA of a new version of its popular Fraxel re:store Dual Laser System to clear pigmentation and other superficial skin conditions. The device with a 1550 nanometer (nm) wavelength already has the regulatory approval for skin resurfacing and treatment of pigmented lesions and certain other skin conditions.

Lumenis Inc has launched the AcuPulse(TM) Fractional CO2 Laser System for aesthetic applications at the American Society of Dermatologic Surgery’s annual meeting in Phoenix. The AcuPulse(TM) gives physicians an affordable and efficient solution to their Pulsed Fractional Skin Resurfacing needs. Pulsed CO2 lasers are superior in the treatment of wrinkles, skin dyschromias, certain types of scars and the Lumenis’ AcuPulse(TM) brings its SuperPulse(TM) technology with the unmatched fractional scanning excellence of the Lumenis portfolio to give physicians an excellent solution for their practice.

Two FDA advisory committees voted in favor of the approval of Purdue Pharma’s reformulated version of long-acting OxyContin, despite some members’ concerns over the drug’s safety. The OxyContin drug designed to be abuse-deterrent. The reformulated version of OxyContin (oxycodone HCl) would be slightly safer than the current product, although its safety profile for the majority of users is still doubtful, according to David Margolis, the professor of dermatology and epidemiology at the University of Pennsylvania.